Overview

A Study to Assess the Safety and Efficacy of Nitric Oxide Injection Into Unresectable Solid Primary or Metastatic Tumors

Status:
Not yet recruiting

Trial end date:
2023-04-30

Target enrollment:

Participant gender:

Summary

This is a phase 1, open-label, dose-escalation and dose-expansion study comprised of a screening period, a single treatment session, and follow-up period of up to 60±5 days post-treatment.

Phase:

Phase 1

Details

Lead Sponsor:

Beyond Air Inc.

Treatments:

Nitric Oxide